Source comparison
MK-677 Dose Response Research: Trial Protocols Comparison
The table below synthesizes findings from five landmark mk-677 dose response research trials, highlighting the nonlinear relationship between dose, GH/IGF-1 elevation, body composition changes, and adverse event incidence. These data inform protocol design for
This comparison does not assign a generated winner or score.
- The table below synthesizes findings from five landmark mk-677 dose response research trials, highlighting the nonlinear relationship between dose, GH/IGF-1 elevation, body composition changes, and adverse event incidence. These data inform protocol design for metabolic and anabolic research applications.
- Chapman et al., JCEM (1997)
- 5mg–75mg daily
- 189% at 25mg; 204% at 50mg
- 55% at 25mg; 61% at 50mg
- Not measured
- 12% at 25mg; 31% at 50mg
- Dose response plateaus at 25mg. Higher doses add risk without proportional GH benefit
- Nass et al., J Gerontol (2008)
- 5mg, 12.5mg, 25mg daily
- 97% at 12.5mg; 176% at 25mg
- 42% at 12.5mg; 58% at 25mg
- 1.9kg at 12.5mg; 2.4kg at 25mg
- 8% at 12.5mg; 14% at 25mg
- 25mg consistently outperforms lower doses for LBM accrual without excessive side effect burden
- Svensson et al., JCEM (1998)
- 10mg, 25mg daily (6 months)
- 82% at 10mg; 168% at 25mg
- 39% at 10mg; 52% at 25mg
- 1.1kg at 10mg; 2.2kg at 25mg
- 6% at 10mg; 11% at 25mg
- Sustained 25mg dosing maintains GH elevation across 24 weeks with acceptable glucose impact
- Murphy et al., Horm Metab Res (2001)
- 25mg, 50mg daily
- 181% at 25mg; 197% at 50mg
- 54% at 25mg; 62% at 50mg
- 2.4kg at 25mg; 2.8kg at 50mg
- 13% at 25mg; 34% at 50mg
- 50mg produces marginal additional LBM gain but doubles metabolic side effects. Poor risk-benefit
- Bach et al., Growth Horm IGF Res (2004)
- 12.5mg daily vs 25mg daily
- 118% at 12.5mg; 193% at 25mg
- 41% at 12.5mg; 59% at 25mg
- 1.6kg at 12.5mg; 2.5kg at 25mg
- 7% at 12.5mg; 15% at 25mg
- Doubling from 12.5mg to 25mg produces proportional anabolic benefit; further escalation does not